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Abstract 
Review on STAG2, with data on DNA/RNA, on the 
protein encoded and where the gene is implicated. 
Identity 
Other names: SA-2, SA2, SCC3B, bA517O1.1 




The STAG2 gene consists of 35 exons spanning 
142 Kbp, located at chromosome Xq25. 
Transcription 
Transcription takes place in a centromere --> 
telomere orientation (plus strand). Transcription of  
STAG2 gene generates 19 different mRNA 
transcripts, the longest is 6045 bp containing 34 
exons (ENST00000371160). 
There are multiple transcription factor binding site  
(TFBS) for GATA3 present in the regulatory first 
intron of STAG2 summarized above (Fig. 1). 
Pseudogene 
There are no known pseudogenes. 
Protein 
Description 
The STAG2 gene encodes two alternative isoforms: 
- A: Q8N3U4-1, 1231 aa, 141.3 KDa 
- B: Q8N3U4-2, 1268 aa, 145.7 KDa 
Expression 
STAG2 mRNA is expressed in cells from most 
tissues. Peak expression occurs in T-cell and early 
erythroid compartments, and in the uterus. 
 
Figure 1. Clustering of GATA3 TFBS in STAG2 regulatory region. Schema showing multiple GATA3 TFBS present in the 
regulatory intron of STAG2. For additional TFBS see: SABiosciences. 
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Figure 2. Domain structure of STAG2 and amino acid sequence. 
 
Lowest expression is found in brain, heart, liver, 
lung and testis. STAG2 is also overexpressed in T-
/B-cell acute lymphoblastic leukemia (ALL) and in 
other hematopoietic neoplasias, followed by small 
cell lung cancer, neuroblastoma and 
medulloblastoma. 
It has been reported that the expression of STAG2 
protein is lost in some cancer types such as 
glioblastoma, Ewing's sarcoma, and melanoma 
(Solomon et al., 2011), colorectal carcinomas, 
gastric carcinomas and prostate carcinomas (Kim et 
al., 2012). 
Localisation 
Nucleus albeit reportedly with transmembrane 
potential. 
Function 
STAG2 forms the cohesin complex together with 
SMC1, SMC3, and SCC1. The cohesin complex is 
a ring-like structure and is required for cohesion of 
sister chromatids after DNA replication.  
The complex is cleaved at the metaphase-anaphase 
transition and dissociates from chromatin for 
separation of sister chromatids (Xiao et al., 2011). 
While STAG2 mediates centromere cohesion, that 
of telomeres is mediated by the homologous 
STAG1 (Canudas et al., 2009; Remeseiro et al., 
2012). 
Cohesin also plays a major part in the organization 
of interphase chromatin, including the orchestration 
of gene expression in relation to cell cycle where 
STAG2 also plays a key role along with the 
universal transcriptional repressor CCCTC-binding 
factor (CTCF). CTCF-cohesin interactions require 
contact between STAG2 and C-terminal CTCF 
which facilitate recruitment of other cohesion 
complex proteins and formation of the cohesion 
ring. This interaction is also needed for CTCF to 
function as a transcriptional insulator. 
Homology 
Two paralogs are known: STAG1 and STAG3 
which can replace STAG2 in the cohesion complex. 
 
Figure 3. Cohesin complex showing ring structure. 
Diagram showing ring structure of cohesin complex 
(modified from Hagstrom and Meyer, 2003, and Remeseiro 
and Losada, 2013). 
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Figure 4. Cytogenetic analysis of t(X;11) effecting juxtaposition of STAG2 and LMO2. Image shows FISH analysis of 
t(X;11)(q25;p13) in a T-ALL cell line (DSM ACC 437). Note that this translocation is cryptic in G-banding (Fig. A). FISH using 
BAC and fosmid clones (Fig. B, C) places breakpoints in MOLT-14 and another T-ALL cell line PER-117, both inside the first 
(regulatory) intron of STAG2. In both cell lines expression of STAG2 is lost, attributable to divestment of this region which 
includes a deeply conserved cluster of regulatory motifs, including transcription factor binding sites and DNaseI sensitive sites. 
Upregulation of LMO2 in both cell lines occurred, concomitant with acquisition of the upstream STAG2 region. Fig. D: Genomic 
map of Xq25 showing breakpoints in regulatory region in relation to clones used for FISH. Figure redrawn and updated from 




Recurrent STAG2 gene mutations were reported in 
glioblastoma, melanoma and Ewing's sarcoma 
(Solomon et al., 2011). Recently, STAG2 gene was 
found frequently mutated in myeloid neoplasms, 
including acute myeloid leukemia (AML), 
myelodysplastic syndromes (MDS), chronic 
myelomonocytic leukemia (CMML), chronic 
myelogenous leukemia (CML) and classical 
myeloproliferative neoplasms (MPN) (Kon et al., 
2013). Other studies observed lower frequencies of 
STAG2 mutation (Chung et al., 2012; Kim et al., 
2012).It remains unclear whether mutations 
affecting STAG2 operate to induce aneuploidy 
(Solomon et al., 2011; Kolodner et al., 2011), or 
simply to abrogate expression (Rocquain et al., 







Mutation and deletion of the STAG2 gene was 
identified in 5.8% (13/224) of MDS, 10.2% (9/88) 
of CMML, 6.4% (10/157) of AML, 3.1% (2/64) of 
CML, and 1.3% (1/77) of MPN: the STAG2 
alterations were mostly exclusive with alterations 
involving other components of cohesin complex 
(SMC1, SMC3, and RAD21) and were significantly 
associated with mutations in TET2, ASXL1, and 
EZH2 (Kon et al., 2013). 
t(X;11)(q25;p13) 
Disease 
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Cytogenetics 
t(X;11)(q25;p13) in MOLT-14 cells and 
t(X;1;11)(q25;p13;p13) in PER-117 cells. The 
rearrangement is fully cryptic (see below). 
Oncogenesis 
t(X;11)(q25;p13) results in simultaneous 
upregulation of LMO2 and silencing of STAG2 by 
juxtaposition of the far upstream region of LMO2 
with the first regulatory intron of STAG2 (Chen et 
al., 2011). 
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